FCFernando Cabral

Fernando Cabral

*This is an algorithmically generated author record based on publicly available information.

Fernando Cabral has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Anutosh Ganguly

    Research Service, Ann Arbor Veterans Affairs (VA) Healthcare System, Department of Veterans Affairs Health System, Ann Arbor, MI, USA

    13 shared publications
  • Hailing Yang

    Authors' Affiliations: 1Department of Physiology and Pharmacology, Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada; 2Department of Integrative Biology and Pharmacology, University of Texas Medical School; and 3University of Texas, MD Anderson Cancer Center, Houston, Texas

    9 shared publications
  • Rajat Bhattacharya

    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

    7 shared publications
  • Shanghua Yin

    Department of Integrative Biology and Pharmacology, University of Texas Medical School, 6431 Fannin St., Houston, Texas 77030, USA

    4 shared publications
  • Kamala D. Patel

    Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada

    2 shared publications
  • Anthony Frankfurter

    Department of Biology, University of Virginia, Charlottesville, Virginia

    1 shared publication

Latest Publications

  • Microtubule Dynamics Control Tail Retraction in Migrating Vascular Endothelial Cells

    by Anutosh Ganguly, Hailing Yang, Hong Zhang, Fernando Cabral, Kamala D. Patel

    Drugs that target microtubules are potent inhibitors of angiogenesis, but their mechanism of action is not well understood. To explore this, we treated human umbilical vein endothelial cells with paclitaxel, vinblastine, and colchicine and measured the effects on microtubule dynamics and cell motility. In general, lower drug concentrations suppressed microtubule dynamics and inhibited cell migration whereas higher concentrations were needed to inhibit cell division; however, surprisingly, large drug-dependent differences were seen in the relative concentrations needed to inhibit these two processes. Suppression of microtubule dynamics did not significantly affect excursions of lamellipodia away from the nucleus or prevent cells from elongating; but, it did inhibit retraction of the trailing edges that are normally enriched in dynamic microtubules, thereby limiting cell locomotion. Complete removal of microtubules with a high vinblastine concentration caused a loss of polarity that resulted in roundish, rather than elongated, cells, rapid but nondirectional membrane activity, and little cell movement. The results are consistent with a model in which more static microtubules stabilize the leading edge of migrating cells, whereas more dynamic microtubules locate to the rear where they can remodel and allow tail retraction. Suppressing microtubule dynamics interferes with tail retraction, but removal of microtubules destroys the asymmetry needed for cell elongation and directional motility. The prediction that suppressing microtubule dynamics might be sufficient to prevent angiogenesis was supported by showing that low concentrations of paclitaxel could prevent the formation of capillary-like structures in an in vitro tube formation assay. Mol Cancer Ther; 12(12); 2837–46. ©2013 AACR.


  • Open Access

    The Role of Microtubules and Their Dynamics in Cell Migration

    by Anutosh Ganguly, Hailing Yang, Ritu Sharma, Kamala D. Patel, Fernando Cabral


  • Random Mutagenesis of β-Tubulin Defines a Set of Dispersed Mutations That Confer Paclitaxel Resistance

    by Shanghua Yin, Changqing Zeng, Malathi Hari, Fernando Cabral

    Previous research showed that mutations in β1-tubulin are frequently involved in paclitaxel resistance but the question of whether the mutations are restricted by cell-type specific differences remains obscure. To circumvent cellular constraints, we randomly mutagenized β-tubulin cDNA, transfected it into CHO cells, and selected for paclitaxel resistance. A total of 26 β1-tubulin mutations scattered throughout the sequence were identified and a randomly chosen subset were confirmed to confer paclitaxel resistance using site-directed mutagenesis of β-tubulin cDNA and transfection into wild-type cells. Immunofluorescence microscopy and biochemical fractionation studies indicated that cells expressing mutant tubulin had decreased microtubule polymer and frequently suffered mitotic defects that led to the formation of large multinucleated cells, suggesting a resistance mechanism that involves destabilization of the microtubule network. Consistent with this conclusion, the mutations were predominantly located in regions that are likely to be involved in lateral or longitudinal subunit interactions. Notably, fourteen of the new mutations overlapped previously reported mutations in drug resistant cells or in patients with developmental brain abnormalities. A random mutagenesis approach allowed isolation of a wider array of drug resistance mutations and demonstrated that similar mutations can cause paclitaxel resistance and human neuronal abnormalities.


  • Control of MCAK degradation and removal from centromeres

    by Anutosh Ganguly, Rajat Bhattacharya, Fernando Cabral

    Mitotic centromere associated kinesin (MCAK) is a kinesin related protein with the ability to stimulate microtubule depolymerization. It is found at spindle poles, where it may be involved in poleward microtubule flux, and at kinetochores and centromeres where it plays a role in correcting chromosome alignment errors. Its microtubule depolymerase activity and recruitment to centromeres is regulated by phosphorylation, but little is known about how MCAK is maintained at appropriate levels. We previously reported that MCAK accumulates during the cell cycle and is then degraded during mitosis. Using proteomic analysis, we have now identified a new phosphorylation site on MCAK that is responsible for its degradation. Mutation of the site to prevent phosphorylation prolonged the stability of the protein beyond the metaphase to anaphase transition and into the subsequent cell cycle whereas a phosphomimetic mutation accelerated degradation. Unexpectedly, the mutation that prevented phosphorylation also inhibited the removal of MCAK from centromeres causing it to remain attached throughout the cell cycle. Even low expression of phosphorylation‐resistant MCAK delayed mitosis and interfered with cell division. Mitotic defects were also observed by overexpressing a green fluorescent protein‐tagged version of wild‐type MCAK that similarly escaped degradation and accumulated to toxic levels, but did not remain associated with kinetochores during interphase. The results demonstrate that degradation is an important mechanism for controlling the activity of MCAK. © 2012 Wiley Periodicals, Inc


  • Open Access

    Mitotic Centromere-associated Kinesin (MCAK) Mediates Paclitaxel Resistance

    by Anutosh Ganguly, Hailing Yang, Mesias Pedroza, Rajat Bhattacharya, Fernando Cabral


  • Open Access

    The arresting action of microtubules in cell motility

    by Anutosh Ganguly, Fernando Cabral

    Comment on: Ganguly A, et al. Oncotarget 2011; 2:368-77.


  • Open Access

    Overexpression of Mitotic Centromere–Associated Kinesin Stimulates Microtubule Detachment and Confers Resistance to Paclitaxel

    by Anutosh Ganguly, Hailing Yang, Fernando Cabral

    Numerous studies have implicated mutations in tubulin or the overexpression of specific tubulin genes in resistance to microtubule-targeted drugs. Much less is known about the role of accessory proteins that modulate microtubule behavior in the genesis of drug resistance. Here, we examine mitotic centromere–associated kinesin (MCAK), a member of the kinesin family of microtubule motor proteins that has the ability to stimulate microtubule depolymerization, and show that overexpressing the protein confers resistance to paclitaxel and epothilone A, but increases sensitivity to colcemid. Cells transfected with FLAG-tagged MCAK cDNA using a tet-off–regulated expression system had a disrupted microtubule cytoskeleton and were able to survive a toxic concentration of paclitaxel in the absence, but not in the presence of tetracycline, showing that drug resistance was caused by ectopic MCAK production. Moreover, a population that was heterogeneous with respect to FLAG-MCAK expression became enriched with cells that produced the ectopic protein when it was placed under paclitaxel selection. Similar to previously isolated mutants with altered tubulin, paclitaxel resistant cells resulting from MCAK overexpression were found to have decreased microtubule polymer and a seven-fold increase in the frequency of microtubule detachment from centrosomes. These data are consistent with a model for paclitaxel resistance that is based on stability of the attachment of microtubules to their nucleating centers, and they implicate MCAK in the mechanism of microtubule detachment. Mol Cancer Ther; 10(6); 929–37. ©2011 AACR.


  • Open Access

    Class III β-Tubulin Counteracts the Ability of Paclitaxel to Inhibit Cell Migration

    by Anutosh Ganguly, Hailing Yang, Fernando Cabral

    Class III β-Tubulin Counteracts the Ability of Paclitaxel to Inhibit Cell Migration